{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:50:32Z","timestamp":1787237432612,"version":"build-2736575974"},"reference-count":56,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000005","name":"United States Department of Defense","doi-asserted-by":"publisher","award":["HT94252310175"],"award-info":[{"award-number":["HT94252310175"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute Cancer Center Support","doi-asserted-by":"publisher","award":["P30CA225520"],"award-info":[{"award-number":["P30CA225520"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Background: Our objective was to identify and validate proteins that predict which patients with ovarian cancer will respond to SHetA2, an investigational drug in a phase 1 trial for patients with advanced or recurrent solid tumors (clinicaltrials.gov: NCT04928508). Methods: Cells were cultured from ascites from nine consented patients under an institutional review board-approved protocol. SHetA2 or olaparib sensitivities were determined using metabolic viability assays in ascites-derived cultures or ovarian cancer cell lines. Expression of four SHetA2 target proteins and sixteen proteins previously identified in an ovarian cancer mouse model were measured using microcapillary electrophoresis. Triosephosphate isomerase 1 (TPI1) was modulated by siRNA or lentivirus vector-mediated overexpression. Metabolites were measured using mass spectrometry. Results: TPI1 was elevated in SHetA2-sensitive compared to SHetA2-resistant ascites-derived cultures (two-way ANOVA q-value = 0.0003). The majority of (5\/9) cultures were olaparib-resistant and SHetA2-sensitive. TPI1 was higher in olaparib-resistant cultures (two-way ANOVA q-value = 0.0003). Reduction in or overexpression of TPI1 reduced or increased SHetA2 potency, respectively, in two ovarian cancer cell lines (t-tests; p &lt; 0.05). SHetA2 reduced the metabolites in glycolysis downstream of TPI1, the tricarboxylic acid cycle and oxidative pentose phosphate pathway. Conclusions: TPI1 is a candidate functional biomarker of SHetA2 sensitivity in ovarian cancer.<\/jats:p>","DOI":"10.3390\/cells15030267","type":"journal-article","created":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T14:35:46Z","timestamp":1769783746000},"page":"267","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Identification and Experimental Validation of Triosephosphate Isomerase 1 as a Functional Biomarker of SHetA2 Sensitivity in Ovarian Cancer"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5305-3486","authenticated-orcid":false,"given":"Laura F.","family":"Mortan","sequence":"first","affiliation":[{"name":"Gynecologic Oncology Section, Stephenson Cancer Center, University of Oklahoma Health Campus, Oklahoma City, OK 73104, USA"},{"name":"Pathology Department, University of Oklahoma Health Campus, Oklahoma City, OK 73104, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1403-0334","authenticated-orcid":false,"given":"Zitha Redempta","family":"Isingizwe","sequence":"additional","affiliation":[{"name":"Gynecologic Oncology Section, Stephenson Cancer Center, University of Oklahoma Health Campus, Oklahoma City, OK 73104, USA"},{"name":"Obstetrics and Gynecology Department, College of Medicine, University of Oklahoma Health Campus, Oklahoma City, OK 73104, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7606-8245","authenticated-orcid":false,"given":"Doris Mangiaracina","family":"Benbrook","sequence":"additional","affiliation":[{"name":"Gynecologic Oncology Section, Stephenson Cancer Center, University of Oklahoma Health Campus, Oklahoma City, OK 73104, USA"},{"name":"Pathology Department, University of Oklahoma Health Campus, Oklahoma City, OK 73104, USA"},{"name":"Obstetrics and Gynecology Department, College of Medicine, University of Oklahoma Health Campus, Oklahoma City, OK 73104, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,30]]},"reference":[{"key":"ref_1","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA A Cancer J. Clin."},{"key":"ref_2","unstructured":"Arora, T., Mullangi, S., Vadakekut, E.S., and Lekkala, M.R. (2024). Epithelial Ovarian Cancer. StatPearls."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ygyno.2011.08.014","article-title":"An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT)","volume":"124","author":"Chi","year":"2012","journal-title":"Gynecol. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3802\/jgo.2013.24.1.83","article-title":"Advanced ovarian cancer: What should be the standard of care?","volume":"24","author":"Goff","year":"2013","journal-title":"J. Gynecol. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1001\/jama.2025.9495","article-title":"Ovarian Cancer: A Review","volume":"334","author":"Caruso","year":"2025","journal-title":"JAMA"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Matulonis, U.A., Sood, A.K., Fallowfield, L., Howitt, B.E., Sehouli, J., and Karlan, B.Y. (2016). Ovarian cancer. PRIMER, Macmillan Publishers Limited.","DOI":"10.1038\/nrdp.2016.61"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ajpath.2020.09.006","article-title":"The Origin of Ovarian Cancer Species and Precancerous Landscape","volume":"191","author":"Shih","year":"2021","journal-title":"Am. J. Pathol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/nrc.2016.113","article-title":"The disparate origins of ovarian cancers: Pathogenesis and prevention strategies","volume":"17","author":"Karnezis","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.2353\/ajpath.2010.100105","article-title":"Ovarian Cancer Development and Metastasis","volume":"177","author":"Lengyel","year":"2010","journal-title":"Am. J. Pathol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10147-012-0396-6","article-title":"Malignant ascites: Pathophysiology and treatment","volume":"18","author":"Cavazzoni","year":"2013","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41416-020-0875-x","article-title":"The untapped potential of ascites in ovarian cancer research and treatment","volume":"123","author":"Ford","year":"2020","journal-title":"Br. J. Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Almeida-Nunes, D.L., Mendes-Frias, A., Silvestre, R., Dinis-Oliveira, R.J., and Ricardo, S. (2022). Immune Tumor Microenvironment in Ovarian Cancer Ascites. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms231810692"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s12079-022-00698-8","article-title":"Friend and foe: The regulation network of ascites components in ovarian cancer progression","volume":"17","author":"Geng","year":"2023","journal-title":"J. Cell Commun. Signal."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Mortan, L.F., Bohn, J.A., and Benbrook, D.M. (2025). Increased IGF2 and Immunosuppressive Cell Populations in Ascites of Patients with Recurrent High-Grade Serous Ovarian Cancer. Biomedicines, 13.","DOI":"10.3390\/biomedicines13092074"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"189346","DOI":"10.1016\/j.bbcan.2025.189346","article-title":"Deciphering the \u201cRosetta Stone\u201d of ovarian cancer stem cells: Opportunities and challenges","volume":"1880","author":"Tan","year":"2025","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/s12943-025-02345-3","article-title":"A comprehensive overview of ovarian cancer stem cells: Correlation with high recurrence rate, underlying mechanisms, and therapeutic opportunities","volume":"24","author":"Alizadeh","year":"2025","journal-title":"Mol. Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/s41416-020-0865-z","article-title":"Ascites-derived ALDH+CD44+ tumour cell subsets endow stemness, metastasis and metabolic switch via PDK4-mediated STAT3\/AKT\/NF-\u03baB\/IL-8 signalling in ovarian cancer","volume":"123","author":"Jiang","year":"2020","journal-title":"Br. J. Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Jiang, Y.-X., Siu, M.K.Y., Wang, J.-J., Leung, T.H.Y., Chan, D.W., Cheung, A.N.Y., Ngan, H.Y.S., and Chan, K.K.L. (2022). PFKFB3 Regulates Chemoresistance, Metastasis and Stemness via IAP Proteins and the NF-kappaB Signaling Pathway in Ovarian Cancer. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.748403"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.2147\/CMAR.S538281","article-title":"Metabolic Reprogramming Shapes the Progression and Therapeutic Landscape of Ovarian Cancer","volume":"17","author":"Liu","year":"2025","journal-title":"Cancer Manag. Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s40259-015-0125-6","article-title":"Olaparib: A Review of Its Use as Maintenance Therapy in Patients with Ovarian Cancer","volume":"29","author":"Frampton","year":"2015","journal-title":"BioDrugs"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ygyno.2021.07.016","article-title":"Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial","volume":"163","author":"Colombo","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"38","DOI":"10.7150\/jca.49406","article-title":"Current Ovarian Cancer Maintenance Strategies and Promising New Developments","volume":"12","author":"Gogineni","year":"2021","journal-title":"J. Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/ijc.32830","article-title":"Novel ovarian cancer maintenance therapy targeted at mortalin and mutant p53","volume":"147","author":"Ramraj","year":"2019","journal-title":"Int. J. Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Benbrook, D.M. (2022). SHetA2 Attack on Mortalin and Colleagues in Cancer Therapy and Prevention. Front. Cell Dev. Biol., 10.","DOI":"10.3389\/fcell.2022.848682"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/s10637-013-0041-x","article-title":"SHetA2 interference with mortalin binding to p66shc and p53 identified using drug-conjugated magnetic microspheres","volume":"32","author":"Benbrook","year":"2013","journal-title":"Investig. New Drugs"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e70088","DOI":"10.1002\/jmv.70088","article-title":"Targeting HSP70-E7 Interaction With SHetA2: A Novel Therapeutic Strategy for Cervical Cancer","volume":"96","author":"Garland","year":"2024","journal-title":"J. Med. Virol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e05592","DOI":"10.1002\/advs.202505592","article-title":"Mortalin and PINK1\/Parkin-Mediated Mitophagy Represent Ovarian Cancer-Selective Targets for Drug Development","volume":"12","author":"Chandra","year":"2025","journal-title":"Adv. Sci."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Mortan, L.F., Meelheim, B.A., Garland, J., Bohn, J.A., Isingizwe, Z.R., and Benbrook, D.M. (2025). Implication of fibroblast growth factor 7 in ovarian cancer metastases and patient survival. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1524606"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1038\/s41596-019-0167-1","article-title":"Systems-level analysis of isotopic labeling in untargeted metabolomic data by X13CMS","volume":"14","author":"Llufrio","year":"2019","journal-title":"Nat. Protoc."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1021\/acs.jproteome.9b00640","article-title":"Skyline for Small Molecules: A Unifying Software Package for Quantitative Metabolomics","volume":"19","author":"Adams","year":"2020","journal-title":"J. Proteome Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"5940","DOI":"10.1021\/acs.analchem.7b00396","article-title":"Metabolite Spectral Accuracy on Orbitraps","volume":"89","author":"Su","year":"2017","journal-title":"Anal. Chem."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3675","DOI":"10.1038\/s41467-024-48009-6","article-title":"MetaboAnalystR 4.0: A unified LC-MS workflow for global metabolomics","volume":"15","author":"Pang","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Amuzu, S., Carmona, E., Mes-Masson, A.-M., Greenwood, C.M.T., Tonin, P.N., and Ragoussis, J. (2021). Candidate Markers of Olaparib Response from Genomic Data Analyses of Human Cancer Cell Lines. Cancers, 13.","DOI":"10.3390\/cancers13061296"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"7419","DOI":"10.1038\/ncomms8419","article-title":"Characterization of twenty-five ovarian tumour cell lines that phenocopy primary tumours","volume":"6","author":"Tan","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.21037\/jgo-2025-130","article-title":"A promising model for prediction of chemotherapeutic sensitivity in gastrointestinal cancers using patient-derived malignant ascites organoids","volume":"16","author":"Yu","year":"2025","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.4143\/crt.2022.1630","article-title":"Establishment of Patient-Derived Organoids Using Ascitic or Pleural Fluid from Cancer Patients","volume":"55","author":"Choi","year":"2023","journal-title":"Cancer Res. Treat."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1111\/cas.13407","article-title":"Characterization of ascites-derived tumor cells from an endometrial cancer patient","volume":"108","author":"Li","year":"2017","journal-title":"Cancer Sci."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Arias-Diaz, A.E., Ferreiro-Pantin, M., Barbazan, J., Perez-Beliz, E., Ruiz-Ba\u00f1obre, J., Casas-Arozamena, C., Muinelo-Romay, L., Lopez-Lopez, R., Vilar, A., and Curiel, T. (2023). Ascites-Derived Organoids to Depict Platinum Resistance in Gynaecological Serous Carcinomas. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241713208"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Carroll, M.J., Kaipio, K., Hynninen, J., Carpen, O., Hautaniemi, S., Page, D., and Kreeger, P.K. (2022). A Subset of Secreted Proteins in Ascites Can Predict Platinum-Free Interval in Ovarian Cancer. Cancers, 14.","DOI":"10.3390\/cancers14174291"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"4570","DOI":"10.18632\/oncotarget.27827","article-title":"Chemotherapy sensitivity testing on ovarian cancer cells isolated from malignant ascites","volume":"11","author":"Zaman","year":"2020","journal-title":"Oncotarget"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.3802\/jgo.2022.33.e44","article-title":"PARP inhibitors in ovarian cancer: Overcoming resistance with combination strategies","volume":"33","author":"Miller","year":"2022","journal-title":"J. Gynecol. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"11592","DOI":"10.18632\/oncotarget.24294","article-title":"MEK inhibition leads to BRCA2 downregulation and sensitization to DNA damaging agents in pancreas and ovarian cancer models","volume":"9","author":"Vena","year":"2018","journal-title":"Oncotarget"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"eaal5148","DOI":"10.1126\/scitranslmed.aal5148","article-title":"Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers","volume":"9","author":"Sun","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.ygyno.2017.06.011","article-title":"Antidiabetic medication, statins and the risk of endometrioid endometrial cancer in patients with type 2 diabetes","volume":"146","author":"Arima","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1002\/prot.25299","article-title":"A guide to the effects of a large portion of the residues of triosephosphate isomerase on catalysis, stability, druggability, and human disease","volume":"85","author":"Cabrera","year":"2017","journal-title":"Proteins Struct. Funct. Bioinform."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Siu, M.K.Y., Jiang, Y.-X., Wang, J.-J., Leung, T.H.Y., Han, C.Y., Tsang, B.K., Cheung, A.N.Y., Ngan, H.Y.S., and Chan, K.K.L. (2019). Hexokinase 2 Regulates Ovarian Cancer Cell Migration, Invasion and Stemness via FAK\/ERK1\/2\/MMP9\/NANOG\/SOX9 Signaling Cascades. Cancers, 11.","DOI":"10.3390\/cancers11060813"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"4305","DOI":"10.18632\/oncotarget.2010","article-title":"Cancer stem cells from epithelial ovarian cancer patients privilege oxidative phosphorylation, and resist glucose deprivation","volume":"5","author":"Bellio","year":"2014","journal-title":"Oncotarget"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/ijc.32616","article-title":"Oxidative phosphorylation as a potential therapeutic target for cancer therapy","volume":"146","author":"Sica","year":"2020","journal-title":"Int. J. Cancer"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1158\/1078-0432.CCR-17-3070","article-title":"Oxidative Phosphorylation as an Emerging Target in Cancer Therapy","volume":"24","author":"Ashton","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/s41591-022-02103-8","article-title":"Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: Phase I trials","volume":"29","author":"Yap","year":"2023","journal-title":"Nat. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ygyno.2023.11.013","article-title":"Manipulation of metabolic responses enhances SHetA2 efficacy without toxicity in cervical cancer cell lines and xenografts","volume":"180","author":"Rai","year":"2023","journal-title":"Gynecol. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Rai, R., Chandra, V., Kennedy, A.L., Zuna, R.E., and Benbrook, D.M. (2022). Distinct mechanism of cervical cancer cell death caused by the investigational new drug SHetA2. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.958536"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s10020-023-00612-x","article-title":"Newly discovered roles of triosephosphate isomerase including functions within the nucleus","volume":"29","author":"Myers","year":"2023","journal-title":"Mol. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/s41419-022-04655-6","article-title":"Elevated nuclear localization of glycolytic enzyme TPI1 promotes lung adenocarcinoma and enhances chemoresistance","volume":"13","author":"Liu","year":"2022","journal-title":"Cell Death Dis."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1038\/s42255-021-00405-8","article-title":"Nuclear dihydroxyacetone phosphate signals nutrient sufficiency and cell cycle phase to global histone acetylation","volume":"3","author":"Zhang","year":"2021","journal-title":"Nat. Metab."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/15\/3\/267\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T14:41:12Z","timestamp":1769784072000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/15\/3\/267"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,30]]},"references-count":56,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["cells15030267"],"URL":"https:\/\/doi.org\/10.3390\/cells15030267","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,30]]}}}